[Report] Opportunities in Stem Cell Technology

In the nascent, but rapidly growing field of stem cell therapies, products are a long way from being commercialized. However, the market potential for stem cell therapies products is very large. This report aims to identify those technologies and opportunities in the United States with the greatest future opportunities, the opportunities to develop enabling technologies in the field, and the organizations and laboratories performing current research. In addition, a section is included that covers the legislative, political and social issues surrounding stem cell technology and research. These issues are impacting the development of the technology.

Objectives

This report is a convenient and comprehensive report on stem cells and the technologies being development. Objectives of the report include the following:

To describe research activities and potential
To outline problems involved in developing these technologies and the fairly rigorous regulatory challenges that companies will be facing when licensing these new therapies.
To provide the kind of current information and analysis the reader will need to make strategic business or investment decisions in the area of stem cell technology.
To provide in-depth information on most companies, organizations, and research facilities involved in the field.

Audience

This report is designed to be used primarily by executives, investors, venture capitalists, and business development managers and analysts involved in the pharmaceutical or biotechnology areas that may have an interest in stem cell technology. Companies and organizations seeking to identify partners with complementary technologies may also find this report valuable.

Stem cell research and the accompanying enabling technologies have virtually exploded since embryonic stem cells were first isolated in 1998. Many of the enabling and complementary technologies impacting stem cells are only now catching up to the rate of research. As such, there is a section on companies supplying the research, including those with cell lines, cell and tissue culture media, and reagents. The report includes detailed profiles and information on:

82 companies involved in the development of stem cell therapeutics, worldwide,
57 academic organizations involved in stem cell research in the U.S.,
19 laboratories outside the U.S. with advanced research in the field,
20 detailed profiles on key companies in the industry,
32 suppliers to the Stem Cell Industry, of media, sera, and reagents specifically intended for stem cell research,
10 organizations on the NIH list as suppliers having embryonic stem cell lines.
149 key researchers at academic organizations worldwide, and
11 key researchers at commercial organizations.

Because of the early stages of product development, near-term estimates on products currently in development would be pure speculation. The vast majority of products to be discussed have yet to be developed, and we expect any projections made here would be shown to be inaccurate within 5 years.

Scope And Content Of Report

Stem cell research and the accompanying enabling technologies have virtually exploded since embryonic stem cells were first isolated in 1998. Many of the enabling and complementary technologies affecting stem cells are only now catching up to the rate of research. As such, there is a section on companies that supply the research companies, including those with cell lines, cell and tissue culture media, and reagents. The report includes detailed profiles and information on the following:

82 companies involved in the development of stem cell therapeutics, worldwide.
19 laboratories outside the United States with advanced research in the field.
20 detailed profiles on key companies in the industry.
32 suppliers to the Stem Cell Industry of media, sera, and reagents specifically intended for stem cell research.
10 organizations on the National Institutes of Health list as suppliers of embryonic stem cell lines.
149 key researchers at academic organizations worldwide.
11 key researchers at commercial organizations.

Because product development is in the early stages, near-term estimates on products currently in development would be pure speculation. The vast majority of products discussed in this report have yet to be developed, and we expect that any projections made here will be shown to be inaccurate within 5 years.

Methodology

The information in this report was taken from primary industry sources; interviews with company, government, and academic organization officials; and company submissions such as 10K reports to the Securities and Exchange Commission, annual reports, biotechnology analyst reports, trade journals, and medical literature. The author contacted more than 30 companies and individuals involved in the development of stem cell products. Research began in the spring of 2001 and was completed by the fall of 2001.

Press Release

New Study Identifies Global Stem Cell Industry Leaders

New York, February 13, 2002 /PR Newswire — A new study released today identifies 13 companies as being in the best position to capitalize on the emerging potential of stem cell technologies. The new study from Kalorama Information and available through MarketResearch.com found several companies from the United States, the United Kingdom, and Australia to be well positioned to succeed.

According to the study, Geron Corporation is currently the dominant organization in the field of stem cell therapy for regenerative medicine. However, the status of that dominance may depend on factors such as commercial rights to develop the cell lines produced for the company, competitive factors, the effectiveness of Geron's technology platform, and other environmental factors.

Kaloramafs analysts based their conclusions about the industry leaders on considerations such as progress in stem cell research and development to date, actual revenue as well as revenue potential, product pipeline, intellectual property, key strategic alliances, quality of management and personnel, key acquisitions and agreements, marketing considerations, and manufacturing and regulatory factors.

gMany of the companies active in the field are also active in other therapeutic areas that can generate revenue while stem cell therapies remain in development,h notes Eric Langer, the author of the study. gGiven the long development cycle for stem cell products and the associated costs involved, these are the companies that will be most able to realize commercial success with stem cells.h

The study culminated in an exhaustive 400-page report entitled Opportunities in Stem Cell Technology, reviewing all the strategic challenges for this nascent but highly promising field. Technologies, funding (governmental and private), regulation, ethics, licensing and partnership deals, key support technologies, research facilities, and profiles of all the major competitors are included.